NCT04952493View on ClinicalTrials.gov

Anlotinib or Penpulimab in Combination With RAI for DTC

PHASE2UnknownINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

September 15, 2021

Primary Completion Date

July 20, 2023

Study Completion Date

July 20, 2024

Conditions
Thyroid Cancer
Interventions
DRUG

Anlotinib hydrochloride

Anlotinib hydrochloride may stop the growth of tumor cells and improve iodine uptake.

DRUG

Sodium Iodide I 131

RAI treatment may shrink the tumor

DRUG

Penpulimab

Penpulimab is a novel structure Immune checkpoint inhibitor. The combination of Penpulimab and RAI might have synergistic effects for DTC.

Trial Locations (1)

100730

RECRUITING

Peking Union Medical College Hospital, Beijing

Sponsors
All Listed Sponsors
collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

lead

Peking Union Medical College Hospital

OTHER